Diagnosis of Alzheimer’s Disease in the Preclinical Stage

In 2015, the number of Alzheimer’s disease (AD) cases in the world was 44 million. This number is anticipated to double by 2030. As per the center for disease control (CDC), AD counts as the number 6 cause of death in the United States. AD is a multifactorial disease with its formation still not fully grasped. Neurodegeneration and Beta-Amyloid peptide deposition are believed to be the pathology behind the development of AD. The preclinical stage comes to be a central research focus as it has been claimed that early obtrusion may offer the best chance of therapeutic accomplishment.